Munster PN - Search Results

1

Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.

Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE Jr, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Buzdar A, et al. Among authors: munster pn. J Clin Oncol. 2003 Mar 15;21(6):1007-14. doi: 10.1200/JCO.2003.06.108. J Clin Oncol. 2003. PMID: 12637464 Clinical Trial.

2

High-dose therapy for breast cancer.

Hudis CA, Münster PN. Hudis CA, et al. Among authors: munster pn. Semin Oncol. 1999 Feb;26(1):35-47. Semin Oncol. 1999. PMID: 10073560 Review.

3

Adjuvant therapy for resectable breast cancer.

Münster PN, Hudis CA. Münster PN, et al. Hematol Oncol Clin North Am. 1999 Apr;13(2):391-413, vi. doi: 10.1016/s0889-8588(05)70062-9. Hematol Oncol Clin North Am. 1999. PMID: 10363137 Review.

4

Role of taxanes in adjuvant therapy.

Münster PN, Hudis CA. Münster PN, et al. Cancer Invest. 2000;18(1):32-8. doi: 10.3109/07357900009023060. Cancer Invest. 2000. PMID: 10701365 Review. No abstract available.

5

Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.

Münster PN, Buzdar A, Dhingra K, Enas N, Ni L, Major M, Melemed A, Seidman A, Booser D, Theriault R, Norton L, Hudis C. Münster PN, et al. J Clin Oncol. 2001 Apr 1;19(7):2002-9. doi: 10.1200/JCO.2001.19.7.2002. J Clin Oncol. 2001. PMID: 11283133 Clinical Trial.

6

Arzoxifene: the development and clinical outcome of an ideal SERM.

Munster PN. Munster PN. Expert Opin Investig Drugs. 2006 Mar;15(3):317-26. doi: 10.1517/13543784.15.3.317. Expert Opin Investig Drugs. 2006. PMID: 16503767 Review.

7

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.

Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW. Munster PN, et al. Clin Cancer Res. 2007 Feb 15;13(4):1238-45. doi: 10.1158/1078-0432.CCR-06-1539. Clin Cancer Res. 2007. PMID: 17317835 Clinical Trial.

8

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.

Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Münster P, et al. J Clin Oncol. 2007 May 20;25(15):1979-85. doi: 10.1200/JCO.2006.08.6165. J Clin Oncol. 2007. PMID: 17513804 Clinical Trial.

9

Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.

Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D. Moulder S, et al. Cancer. 2008 Nov 15;113(10):2646-54. doi: 10.1002/cncr.23916. Cancer. 2008. PMID: 18823053 Free article. Clinical Trial.

10

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Daud AI, et al. Among authors: munster pn. J Clin Oncol. 2008 Dec 20;26(36):5896-903. doi: 10.1200/JCO.2007.15.6794. Epub 2008 Nov 24. J Clin Oncol. 2008. PMID: 19029422 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

168 results

Search Page

Filters